Investigations outlined here demonstrated that the mAb developed was capable of specifically interacting with MUC18 on melanoma cells, initiating downstream signaling events that were associated with inhibition of melanoma cell proliferation, migration, and invasion in vitro, and reduction in tumor growth and metastasis in vivo. Here, MCAM is linked to melanoma.